On March 30, BullFrog AI signed a commercial agreement with a top 5 global pharmaceutical company by revenue. The agreement utilizes the proprietary bfLEAP® platform to identify and prioritize therapeutic targets for Major Depressive Disorder (MDD). The MDD market was valued at over $8 billion in 2025 and is expected to exceed $11 billion by 2032.
